• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rezolute Inc. (Amendment)

    1/18/24 10:29:32 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    SC 13G/A 1 rzlt1576-form.htm

    OMB APPROVAL

    OMB Number: 3235-0145

    Estimated average burden hours per response ….11

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5*)

    REZOLUTE, INC.

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    76200L309

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
      Rule 13d-1(c)
      Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     

     

    CUSIP No.: 76200L309

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Federated Hermes, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:         8,250,274
    6. Shared Voting Power
    7. Sole Dispositive Power:         8,250,274
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:         8,250,274
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  19.99%
    12. Type of Reporting Person (See Instructions): HC

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Voting Shares Irrevocable Trust
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:         8,250,274
    6. Shared Voting Power
    7. Sole Dispositive Power:         8,250,274
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:         8,250,274
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  19.99%
    12. Type of Reporting Person (See Instructions): OO

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Thomas R. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:         8,250,274
    7. Sole Dispositive Power
    8. Shared Dispositive Power:         8,250,274

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:         8,250,274
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  19.99%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Ann C. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:         8,250,274
    7. Sole Dispositive Power
    8. Shared Dispositive Power:         8,250,274

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:         8,250,274
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  19.99%
    12. Type of Reporting Person (See Instructions):IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      J. Christopher Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:         8,250,274
    7. Sole Dispositive Power
    8. Shared Dispositive Power:         8,250,274

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:         8,250,274
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  19.99%
    12. Type of Reporting Person (See Instructions): IN

     

    Item 1.

    (a) Name of Issuer
       REZOLUTE, INC.
    (b) Address of Issuer’s Principal Executive Offices
      275 Shoreline Drive, Suite 500
      Redwood City, CA  94065

    Item 2.

    (a) Name of Person Filing: Federated Hermes, Inc.
    (b) Address Of Principal Business Office or, if none, Residence
      1001 Liberty Avenue, Pittsburgh, PA  15222-3779
    (c) Citizenship: Pennsylvania
    (d) Title of Class of Securities
      Common Stock
    (e) CUSIP Number: 76200L309
    Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
    (f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
    (g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    A. Federated Hermes, Inc.
    (a) Amount beneficially owned:         8,250,274
    (b) Percent of class:  19.99%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:         8,250,274
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:         8,250,274  
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    B. Voting Shares Irrevocable Trust
    (a) Amount beneficially owned:         8,250,274
    (b) Percent of class:  19.99%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:         8,250,274
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:         8,250,274  
      (iv) Shared power to dispose or to direct the disposition of:  0

     

     

    C. Thomas R. Donahue
    (a) Amount beneficially owned:         8,250,274
    (b) Percent of class:  19.99%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:         8,250,274
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:         8,250,274  

     

    D. Ann C. Donahue
    (a) Amount beneficially owned:         8,250,274
    (b) Percent of class:  19.99%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:         8,250,274
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:         8,250,274

     

     

    E. J. Christopher Donahue
    (a) Amount beneficially owned:         8,250,274
    (b) Percent of class:  19.99%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:         8,250,274
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:         8,250,274

     

    Instruction: Dissolution of a group requires a response to this item.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

    Instruction: Dissolution of a group requires a response to this item.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
    Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
    Item 9.Notice of Dissolution of Group: NOT APPLICABLE
    Item 10.Certification
    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
    (b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  January 17, 2024
    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    Date:  January 17, 2024
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date:  January 17, 2024
    By: /s/Ann C. Donahue
    Name/Title: Ann C. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date:  January 17, 2024
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

     
     

     

    EXHIBIT “1”

    ITEM 3 CLASSIFICATION OF REPORTING PERSONS

    Identity and Classification of Each Reporting Person

     

    IDENTITY CLASSIFICATION UNDER ITEM 3
    Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Hermes Insurance Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Equity Management Company of Pennsylvania (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Hermes, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    FII Holdings, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Voting Shares Irrevocable Trust (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Thomas R. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Ann C. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    J. Christopher Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)

    Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the “Investment Advisers”), which act as investment advisers to registered investment companies and separate accounts that own shares of common stock in REZOLUTE, INC. (the “Reported Securities”). The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

     
     

    EXHIBIT “2”

    AGREEMENT FOR JOINT FILING OF

    SCHEDULE 13G

    The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

    1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

    Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

    Thomas R. Donahue, individually and as Trustee

    Ann C. Donahue, individually and as Trustee

    J. Christopher Donahue, individually and as Trustee

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

    It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

    Date: January 17, 2024

    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
       
    By: /s/Ann C. Donahue
    Name/Title Ann C. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust
       
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

    1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

     
     

     

    EXHIBIT “3”

     

     

    EXHIBIT “3”

     

     

     

    Text, letter

Description automatically generated

    Get the next $RZLT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    SEC Filings

    See more
    • Amendment: Rezolute Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - Rezolute, Inc. (0001509261) (Filer)

      6/13/25 4:04:13 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      6/13/25 4:02:45 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rezolute Inc.

      10-Q - Rezolute, Inc. (0001509261) (Filer)

      5/13/25 4:25:34 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Roberts Brian Kenneth bought $10,939 worth of shares (2,500 units at $4.38), increasing direct ownership by 19% to 15,500 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/26/25 9:07:55 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $20,250 worth of shares (5,000 units at $4.05), increasing direct ownership by 2% to 268,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/24/25 12:41:19 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kim Young-Jin bought $3,999,999 worth of shares (1,230,769 units at $3.25) (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/23/25 9:38:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

      REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled "Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress" has been selected for a late-breaking presentation at ENDO 2025 taking place July 12-15, 2025 in San Francisco, CA, USA. "We are excited to share baseline data from the sunRIZE study, which will offer important insights into this population and its comparabilit

      7/9/25 7:30:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

      Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI. "The completion of enrollment in the s

      5/28/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

      sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

      5/13/25 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Roberts Brian Kenneth bought $10,939 worth of shares (2,500 units at $4.38), increasing direct ownership by 19% to 15,500 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/26/25 9:07:55 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $20,250 worth of shares (5,000 units at $4.05), increasing direct ownership by 2% to 268,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/24/25 12:41:19 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kim Young-Jin bought $3,999,999 worth of shares (1,230,769 units at $3.25) (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/23/25 9:38:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Financials

    Live finance-specific insights

    See more
    • Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

      Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

      2/13/24 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports First Quarter Fiscal 2024 Results

      REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o

      11/13/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

      REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20

      9/14/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

      sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

      5/13/25 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

      REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

      3/26/25 7:30:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon

      1/24/24 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 6:59:50 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 10:04:23 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/13/24 5:31:40 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care